# Kisspeptin Restores Placental mTOR Signaling and Improves Glucose Homeostasis Mediators Disrupted by Maternal Hypothyroidism in Rats

**Authors:** Bianca Reis Santos, Jeane Martinha dos Anjos Cordeiro, Luciano Cardoso Santos, Cleisla Souza Oliveira, Maria Clara Pascoal Santos Alvarez, Natália Panhoca Rodrigues, Jorge Lopez‐Tello, Amanda N. Sferruzzi‐Perri, Rogéria Serakides, Juneo Freitas Silva

PMC · DOI: 10.1111/apha.70188 · 2026-03-04

## TL;DR

Kisspeptin helps fix placental and maternal metabolism issues caused by hypothyroidism in pregnant rats, though it doesn't fully reverse all effects.

## Contribution

Kisspeptin-10 is shown to restore placental mTOR signaling and glucose metabolism disrupted by maternal hypothyroidism.

## Key findings

- Maternal hypothyroidism caused glucose intolerance and reduced fetal and placental weights.
- Kisspeptin-10 treatment restored placental AKT/mTOR expression and improved Glut1 dysregulation.
- Kisspeptin-10 upregulated the IGF1/IGF1R axis in hypothyroid pregnant rats.

## Abstract

Reduced placental mTOR signaling is associated with intrauterine growth restriction and impaired maternal and placental metabolism. Since maternal hypothyroidism induces intrauterine growth restriction, and maternal treatment with kisspeptin‐10 (Kp10) has been shown to improve feto‐placental development in hypothyroid rats, this study aimed to evaluate the effects of maternal hypothyroidism, with and without kisspeptin‐10 treatment, on maternal energy homeostasis and placental expression of mTOR and glucose metabolism mediators.

Maternal hypothyroidism was induced by administration of propylthiouracil, and kisspeptin‐10 treatment began on gestational day 8.

Maternal hypothyroidism caused glucose intolerance, decreased insulin and HDL levels, reduced fetal and placental weights, and thinned the placental interhaemal barrier. It also increased INSRβ and AKT, while downregulating placental p‐mTOR/mTOR and Glut1. Although kisspeptin‐10 treatment did not improve maternal glucose homeostasis or prevent feto‐placental growth restriction, it attenuated maternal hypothyroidism‐induced placental Glut1 dysregulation, upregulated the IGF1/IGF1R axis, and restored placental AKT/mTOR expression.

These findings suggest that kisspeptin‐10 treatment in hypothyroid pregnant rats improves placental mTOR signaling and glucose metabolism mediators, highlighting novel pathways through which kisspeptin may modulate placental physiology.

Hypothyroidism disrupts maternal and placental metabolism impairing nutrient sensing, fetal growth, and long‐term metabolic health.Kisspeptin restores placental mTOR signaling and glucose metabolism mediators in hypothyroid pregnant rats.Targeting kisspeptin signaling may represent a novel therapeutic strategy to mitigate pregnancy complications.

Hypothyroidism disrupts maternal and placental metabolism impairing nutrient sensing, fetal growth, and long‐term metabolic health.

Kisspeptin restores placental mTOR signaling and glucose metabolism mediators in hypothyroid pregnant rats.

Targeting kisspeptin signaling may represent a novel therapeutic strategy to mitigate pregnancy complications.

## Linked entities

- **Genes:** insrb (insulin receptor b) [NCBI Gene 245700], AKT1 (AKT serine/threonine kinase 1) [NCBI Gene 207], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475], SLC2A1 (solute carrier family 2 member 1) [NCBI Gene 6513], IGF1 (insulin like growth factor 1) [NCBI Gene 3479], IGF1R (insulin like growth factor 1 receptor) [NCBI Gene 3480]
- **Chemicals:** propylthiouracil (PubChem CID 657298), kisspeptin-10 (PubChem CID 25240297)
- **Diseases:** hypothyroidism (MONDO:0005420)
- **Species:** Rattus norvegicus (taxon 10116)

## Full-text entities

- **Genes:** Atf4 (activating transcription factor 4) [NCBI Gene 79255], Irs1 (insulin receptor substrate 1) [NCBI Gene 25467] {aka IRS1IRM}, Lep (leptin) [NCBI Gene 25608] {aka OB, obese}, Pik3cg (phosphatidylinositol-4,5-bisphosphate 3-kinase, catalytic subunit gamma) [NCBI Gene 298947] {aka Pi3k}, Hif1a (hypoxia inducible factor 1 subunit alpha) [NCBI Gene 29560] {aka HIF1-alpha, MOP1}, Prl (prolactin) [NCBI Gene 24683] {aka Gha1, PRLB, PRLSD1, Prl1a1, Prol, RATPRLSD1}, Igf1 (insulin-like growth factor 1) [NCBI Gene 24482] {aka IGF}, Slc2a1 (solute carrier family 2 member 1) [NCBI Gene 24778] {aka GLUTB, GTG1, Glut1, Gtg3, RATGTG1}, Akt1 (AKT serine/threonine kinase 1) [NCBI Gene 24185] {aka Akt}, Slc2a4 (solute carrier family 2 member 4) [NCBI Gene 25139] {aka Glut4}, Pgf (placental growth factor) [NCBI Gene 94203] {aka Plgf}, Igf1r (insulin-like growth factor 1 receptor) [NCBI Gene 25718] {aka IGF-1 receptor, IGFIRC, Igfr1, JTK13}, Polr2a (RNA polymerase II subunit A) [NCBI Gene 363633] {aka Rpo2-1}, Rptor (regulatory associated protein of MTOR, complex 1) [NCBI Gene 287871] {aka RGD1311784}, Insr (insulin receptor) [NCBI Gene 24954], Kiss1r (KISS1 receptor) [NCBI Gene 78976] {aka Gpr54}, Prl3b1 (prolactin family 3, subfamily B, member 1) [NCBI Gene 24283] {aka Csh2, Ghd15, PL-II, Pl2, RPLII}, Vim (vimentin) [NCBI Gene 81818], Mtor (mechanistic target of rapamycin kinase) [NCBI Gene 56718] {aka Frap1, RAFT1}
- **Diseases:** and placental metabolism (MESH:D010922), reduced neonatal body mass (MESH:D001523), impaired maternal glucose homeostasis (MESH:D044882), insulin resistance (MESH:D007333), preeclampsia (MESH:D011225), IUGR (MESH:D005317), MH (MESH:C535694), hyperadrenocorticism (MESH:D000308), inflammation (MESH:D007249), Hypothyroid (MESH:D007037), Restriction (MESH:D002313), metabolic dysfunction (MESH:D008659), glucose (MESH:D018149), hypoxia (MESH:D000860), body mass gain (MESH:C536030), GDM (MESH:D016640), hemorrhagic (MESH:D006470), obesity (MESH:D009765), weight gain (MESH:D015430), Fetal death (MESH:D005313), Glycemic Dysfunction (MESH:D006331)
- **Chemicals:** triglyceride (MESH:D014280), saline (MESH:D012965), BCIP (-), T4 (MESH:D013974), H2O2 (MESH:D006861), paraffin (MESH:D010232), Hematoxylin (MESH:D006416), HCl (MESH:D006851), biotin (MESH:D001710), Eosin (MESH:D004801), TBS-T (MESH:C027647), Tween-20 (MESH:D011136), Blood glucose (MESH:D001786), Glucose (MESH:D005947), methimazole (MESH:D008713), cholesterol (MESH:D002784), Fast Red (MESH:C005215), citrate (MESH:D019343), TRIzol (MESH:C411644), 6-propyl-2-thiouracil (MESH:D011441), paraformaldehyde (MESH:C003043), lipid (MESH:D008055), Glycogen (MESH:D006003)
- **Species:** Mus musculus (house mouse, species) [taxon 10090], Rattus norvegicus (brown rat, species) [taxon 10116], Homo sapiens (human, species) [taxon 9606], Bos taurus (bovine, species) [taxon 9913]

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12960837/full.md

---
Source: https://tomesphere.com/paper/PMC12960837